Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational topical gel formulation contains 3% sodium pentaborate (also known as sodium penta boric acid pentahydrate) as its active ingredient. Developed by Bezmialem Vakif University, it is specifically designed for the treatment of diabetic foot ulcers, particularly those classified as grade 1 or 2 by the International Working Group of the Diabetic Foot (IWGDF). The formulation utilizes a pluronic copolymer base consisting of F68 and F127 to facilitate topical delivery. Boron is believed to enhance the wound healing process through several mechanisms: it stimulates the migration and proliferation of cells necessary for tissue repair, exerts local anti-inflammatory effects, and possesses antibacterial properties against gram-negative bacteria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium pentaborate gel.